Article

Dasatinib/Celecoxib combination: A new hope in triple negative breast cancer treatment

2021-11-12

Abstract excerpt

Despite the tremendous efforts to implement new paradigms for breast cancer, the disease still remains a major challenge worldwide. Genetic deregulation is evident in all breast cancer subtypes and comprises a multitude of mutated genes and deregulated signaling cascades. In this sense, co-targeting Src and COX-2 signaling cascades have attracted fervent interest. This work explored the probable anti-carcinogenic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dd0fb7fd-cabc-5654-880c-6d54db2de2d5
DOI: 10.21203/rs.3.rs-904306/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dasatinib/Celecoxib combination: A new hope in triple negative breast cancer treatmentDOI 10.21203/rs.3.rs-904306/v1Read

Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of ActionSemantic proximity Read

Genistein Mediated Molecular Pharmacology, Cell-Specific Anti-Breast Cancer Mechanism with Synergistic Effect and in silico Safety MeasurementSemantic proximity Read

Synergistic effects of anlotinib and DDP synergy in breast cancer treatment: inhibiting of cell growth and migration, and augmenting apoptosis and autophagy via modulation of the VEGF/JAK2/STAT3 axisSemantic proximity Read

SRC: A Century of Science Brought to the ClinicSemantic proximity Read

A systems biology-based study to assess the effects of TNF-α ± apigenin in triple-negative breast cancer cell lineSemantic proximity Read

Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.Semantic proximity Read

MiR-424-5p and miR -142-3p Combination Synergistically Regulates the Biological Features of Breast Cancer CellsSemantic proximity Read

COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer CellsSemantic proximity Read

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.Semantic proximity Read

Repurposing celecoxib for ovarian cancer treatment by targeting survivin signalingSemantic proximity Read

Synthesis and Evaluation of Naphthalene Derivatives as Potent STAT3 inhibitors and Agents Against Triple-Negative Breast Cancer Growth and MetastasisSemantic proximity Read

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.Semantic proximity Read